Olga DE LA ROSA,Eleuterio LOMBARDO,Wilfried DALEMANS
申请号：
US16854294
公开号：
US20200261511A1
申请日:
2020.04.21
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.
